CHLL vs. STX, PXS, MXC, HELD, INHC, BELL, KNB, ABDX, PRM, and CNSL
Should you be buying Chill Brands Group stock or one of its competitors? The main competitors of Chill Brands Group include Shield Therapeutics (STX), Provexis (PXS), Argent BioPharma (MXC), Hellenic Dynamics (HELD), Induction Healthcare Group (INHC), Belluscura (BELL), Kanabo Group (KNB), Abingdon Health (ABDX), Proteome Sciences (PRM), and Cambridge Nutritional Sciences (CNSL). These companies are all part of the "medical" sector.
Chill Brands Group (LON:CHLL) and Shield Therapeutics (LON:STX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, community ranking, institutional ownership, analyst recommendations, dividends and risk.
Shield Therapeutics received 209 more outperform votes than Chill Brands Group when rated by MarketBeat users. Likewise, 75.17% of users gave Shield Therapeutics an outperform vote while only 66.67% of users gave Chill Brands Group an outperform vote.
0.0% of Chill Brands Group shares are held by institutional investors. Comparatively, 15.7% of Shield Therapeutics shares are held by institutional investors. 16.2% of Chill Brands Group shares are held by insiders. Comparatively, 56.3% of Shield Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Chill Brands Group has higher earnings, but lower revenue than Shield Therapeutics. Chill Brands Group is trading at a lower price-to-earnings ratio than Shield Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Chill Brands Group had 4 more articles in the media than Shield Therapeutics. MarketBeat recorded 4 mentions for Chill Brands Group and 0 mentions for Shield Therapeutics. Shield Therapeutics' average media sentiment score of 0.76 beat Chill Brands Group's score of 0.06 indicating that Shield Therapeutics is being referred to more favorably in the news media.
Chill Brands Group has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Shield Therapeutics has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500.
Shield Therapeutics' return on equity of -146.62% beat Chill Brands Group's return on equity.
Summary
Shield Therapeutics beats Chill Brands Group on 10 of the 14 factors compared between the two stocks.
Get Chill Brands Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for CHLL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CHLL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Chill Brands Group Competitors List
Related Companies and Tools
